ACADIA Pharmaceuticals (ACAD) & Beyondspring (BYSI) Financial Comparison
ACADIA Pharmaceuticals (NASDAQ: ACAD) and Beyondspring (NASDAQ:BYSI) are both healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their profitability, dividends, institutional ownership, risk, earnings, valuation and analyst recommendations.
This table compares ACADIA Pharmaceuticals and Beyondspring’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
94.0% of ACADIA Pharmaceuticals shares are held by institutional investors. Comparatively, 1.2% of Beyondspring shares are held by institutional investors. 22.3% of ACADIA Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
This is a summary of recent recommendations for ACADIA Pharmaceuticals and Beyondspring, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
ACADIA Pharmaceuticals presently has a consensus price target of $51.27, indicating a potential upside of 90.46%. Beyondspring has a consensus price target of $54.50, indicating a potential upside of 109.86%. Given Beyondspring’s stronger consensus rating and higher probable upside, analysts plainly believe Beyondspring is more favorable than ACADIA Pharmaceuticals.
Valuation & Earnings
This table compares ACADIA Pharmaceuticals and Beyondspring’s gross revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|ACADIA Pharmaceuticals||$17.33 million||192.94||-$271.39 million||($2.46)||-10.94|
Beyondspring has lower revenue, but higher earnings than ACADIA Pharmaceuticals.
Beyondspring beats ACADIA Pharmaceuticals on 6 of the 10 factors compared between the two stocks.
ACADIA Pharmaceuticals Company Profile
ACADIA Pharmaceuticals Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of medicines for central nervous system (CNS) disorders. Its lead drug candidate, NUPLAZID (pimavanserin), is used for the treatment of hallucinations and delusions associated with Parkinson’s disease psychosis (PD Psychosis). NUPLAZID is a selective serotonin inverse agonist (SSIA), preferentially targeting 5-HT2A receptors. The Company is conducting a Phase II trial, referred to as the SERENE Study, designed to examine the efficacy and safety of pimavanserin as a treatment for Alzheimer’s disease (AD) Agitation. It is also conducting a Phase III, six-week, randomized, double-blind, placebo-controlled, multi-center, outpatient study, referred to as the ENHANCE-1 study, designed to examine the use of pimavanserin in patients with schizophrenia.
Beyondspring Company Profile
BeyondSpring Inc. is a global clinical-stage biopharmaceutical company. The Company is focused on the development of cancer therapies. The Company is engaged in advancing its lead product, Plinabulin, into a Phase II/III clinical trial for the reduction of docetaxel chemotherapy-induced severe, grade 4 neutropenia; a Phase II/III clinical trial for the prevention of non-docetaxel chemotherapy-induced severe, grade 4 neutropenia, and a Phase III clinical trial as an anticancer agent in combination with docetaxel in advanced non-small cell lung cancer (NSCLC). Plinabulin has also entered in a Phase I/II clinical trials to investigate its therapeutic potential in combination with the immuno-oncology agent nivolumab. The Company’s BPI-002 program is based on an oral small molecule agent, which induces T-cell activation. The Company’s IkappaB kinase (IKK) program, BPI-003, is based on a small molecule inhibitor of IKK, a protein kinase.
Receive News & Ratings for ACADIA Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ACADIA Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.